BCL2/IGH rearrangements were analysed by polymerase chain reaction (PCR) at diagnosis in paired peripheral blood (PB) and bone marrow (BM) samples from 67 patients with stage I/II follicular lymphoma (FL). Real time quantitative PCR (RQ-PCR) and digital droplet PCR (ddPCR) were performed in cases with a major breakpoint region (MBR+) at diagnosis and after localized radiotherapy and rituximab administration in order to investigate the applicability of ddPCR. The overall ddPCR/RQ-PCR concordance was 81Á9% (113/138 samples) and 97Á5% in the 40/138 with quantifiable disease (RQ-PCR≥10
Follicular lymphoma (FL) is an indolent lymphoproliferative disorder of transformed follicular centre B cells. The translocation t(14;18)(q32;q21), juxtaposing the B-cell lymphoma 2 (BCL2) oncogene to the immunoglobulin heavy chain (IGH) locus is a common genetic event in FL (Klein & DallaFavera, 2008; Sungalee et al, 2014) . It can be detected in 50-65% of FL cases by polymerase chain reaction (PCR) spanning the major breakpoint region (MBR) of this translocation (Von Neuhoff et al, 1998) , whereas most of the remaining cases show the rupture in other regions, namely the minor cluster region (mcr), and the 3 0 MBR and 5 0 mcr (minor BCL2 rearrangements) (Weinberg et al, 2007) . Standardized PCR approaches can detect the BCL2/IGH rearrangement both at diagnosis and during follow-up (FU), with the aim of evaluating minimal residual disease (MRD).
MRD has proven of prognostic value in advanced stage FL treated with conventional chemotherapy or chemo-immunotherapy (Rambaldi et al, 2005; Galimberti et al, 2014) .
In particular, nested PCR, which is an endpoint PCR relying on the detection of the PCR product at the end of the run, is used for the investigation of MBR and mcr rearrangements. A real time TaqMan PCR approach (RQ-PCR) is extensively utilized for the quantification of MBR rearrangements, while no validated assay is yet available for the study of the other breakpoints.
A third generation quantitative method is the droplet digital PCR (ddPCR). This method, based on the partition of the template DNA molecules into water-in-oil droplets in which PCR amplification occurs, seems to provide a greater sensitivity and accuracy for the detection and quantification of molecular targets (Hindson et al, 2011; Day et al, 2013) . However, its reliability as a quantitative method in routine haematological laboratories is still under investigation.
While the majority of FL patients have advanced disease (stage III-IV) at presentation, approximately 30% of newly diagnosed FL cases are in early stage (stage I-II) (Pulsoni et al, 2007) . Stage I/II FL is considered a localized disease that can be adequately treated with radiotherapy (RT) alone (Pulsoni et al, 2007; Pugh et al, 2010) . Despite the limited stage, malignant cells can be found in the peripheral blood (PB) and/or bone marrow (BM) at diagnosis in 60% of patients (Pulsoni et al, 2007) . The present paper reports on the comparison of the RQ-PCR and ddPCR methods in a homogeneous series of patients with stage I/II FL, with the aim of investigating the applicability of ddPCR for BCL2/ IGH MBR-positive (MBR+) cell detection and MRD assessment in the PB and BM, and to validate this new technique by comparing it with conventional strategies.
Materials and methods

Patients' samples and study design
Between April 2000 and February 2015, 67 consecutive patients with a confirmed histological diagnosis of stage I/II FL followed at our Centre were included in the study. All were treated with local RT (24-36 Gy); from April 2006, patients who were MRD+ after RT received the anti-CD20 monoclonal antibody rituximab (R, 375 mg/m 2 , 4-weekly administration). The clinical results of this series were presented at the American Society for Hematology Annual Meeting in 2016 (Pulsoni et al, 2016) and will be reported in detail at a later date. PB and BM samples of the 67 patients were collected at diagnosis and analysed by qualitative PCR to identify the presence of the BCL2/IGH rearrangement. The investigated targets were MBR, mcr and the minor BCL2 rearrangements (3 0 MBR and 5 0 mcr). Patients were considered to be positive for the BCL2/IGH rearrangement when one of the investigated targets was found in at least one compartment. Paraffin-embedded lymph nodes (LN) were studied when available. The MBR+ samples were retrospectively studied by RQ-PCR and ddPCR analysis, depending on the availability of the material, at baseline, as well as after local RT and after R treatment.
Patients defined as marker negative by qualitative approaches (MBRÀ/mcrÀ/minor BCL2À) at diagnosis were also analysed by both RQ-PCR and ddPCR, to investigate the possible presence of the MBR marker not detectable by qualitative methods.
All samples were collected in sodium citrate tubes and maintained at room temperature until further processing. Mononuclear cells (MNC) were isolated from PB and BM samples using a Lymphoprep-based gradient centrifugation (Axis-Shield, Oslo, Norway) and DNA was extracted using the Wizard Genomic DNA purification kit (Promega, Madison, WI, USA). DNA concentration was spectrophotometrically measured (BioPhotometer Eppendorf, Hamburg, Germany).
Qualitative BCL2/IGH rearrangement analysis
Nested PCR for MBR and mcr was performed as reported by Gribben et al (1991) , while the 3 0 MBR and 5 0 mcr subclusters were evaluated by a single-step amplification by using the thermal protocol and the primers described in the BIOMED-2 report (van Dongen et al, 2003) on a 2720 Thermal Cycler (Applied Biosystems, Austin, TX, USA). The reactions were carried out by amplifying samples containing 500 ng target DNA in a 50-ll reaction mix. For MBR and mcr analyses, the two steps of the nested PCR contained: 10 ll buffer 59, 5 ll MgCl 2 25 mmol/l, 1 ll PCR nucleotide MIX 10 mmol/l, 1 ll forward primer (20 pmol/ll), 1 ll reverse primer (20 pmol/ll) and 0Á25 ll of GOTaq Flexi DNA polymerase 5 units/ll (Promega). Conversely, the minor BCL2 rearrangement analysis was performed using: 5 ll buffer 109, 4 ll MgCl 2 25 mmol/l, 1 ll PCR nucleotide MIX 10 mmol/l, 1 ll for each forward primer (10 pmol/ll), 1 ll for the reverse primer (10 pmol/ ll) and 0Á2 ll of AmpliTaq Gold 5 units/ll (Applied Biosystems).
For all PCRs, at least 15 ll of PCR products were analysed by 2% agarose gel electrophoresis (containing ethidium bromide) and visualized under ultraviolet illumination. All rearrangements detected were sequenced using the ABI PRISM 3130 AVANT Genetic Analyser (Life Technologies, Carlsbad, CA, USA) and sequences were evaluated by the nucleotideBasic Local Alignment Search Tool (BLAST; https://blast.ncb i.nlm.nih.gov/Blast.cgi).
Quantitative BCL2/IGH rearrangement analysis RQ-PCR. The BCL2/IGH MBR+ rearrangement was quantified by RQ-PCR using the AbiPrism 7300 sequence detector system (PE Applied Biosystems, Foster City, CA, USA) with oligonucleotides and probes as previously described by Ladetto et al (2001) . The reactions were performed in a 25 ll volume reaction mix containing: 12Á5 ll TaqMan Universal Master-mix (PE Applied Biosystems), 400 nmol/l of primers and 200 nmol/l of probe. All analyses were performed and interpreted according to the guidelines developed within the "European Study Group for MRD detection in Acute Lymphoblastic Leukaemia" (ESG-MRD ALL) (van der Velden et al, 2007) . The sensitivity of the assay was defined by testing serial dilutions of DNA derived from the BCL2/IGH positive DOHH-2 cell line, achieving a limiting dilution of 1:10 À5 . The samples, containing 500 ng target DNA, were amplified in triplicate, while the serial dilution of the DOHH-2 cell line was in duplicate. Standard reagents and consumables supplied by Bio-Rad were used, including cartridges and gaskets, droplet generation oil and droplet reader oil. According to the manufacturer's applications guide, we considered acceptable only the replicates with a number of droplets ≥10 000; for a correct quantification of each experiment, we set the threshold value by manual curation, with a sufficient distance from the background to ensure suitable sensitivity and specificity, as recommended by the manufacture's application guide.
To correctly compare the results obtained by the two approaches, we converted the absolute ddPCR results in logarithmic ones, dividing the concentration of each sample by the concentration of the undiluted DOHH2 cell line.
To perform a comparative analysis between ddPCR and RQ-PCR, each ddPCR sample was tested according to the following criteria: 500 ng of sample DNA were tested in triplicate; in case of technical reasons (lack of material), each sample was analysed at least in duplicate. The cases that were RQ-PCR Q/ddPCRÀ and RQ-PCR PNQ/ddPCRÀ were re-tested, depending on the availability of the material, by ddPCR in six replicates, each with the aim of determining if they could be false positive by RQ-PCR or ddPCR sensitivity failures. Each analysis was performed by including negative controls: MNC DNA from the K562 cell line (Sigma Aldrich, S. Louis, MO, USA) not bearing the translocation and representing the background, was tested 6-fold and a no template control (NTC) was performed 2-fold. All samples were quantified according to the following ratio: [copies/ll MRD sample]/[copies/ll DOHH2 cell line sample]. A sample was considered positive but not quantifiable (PNQ) if no reproducible numbers of droplets were observed (at least one) in the replicates and if the number of positive droplets was ≤3. A sample was considered negative if no positive droplets were observed or if positive droplets were below the background. A sample was considered positive and quantifiable (Q) if the above reported conditions were met.
Results
Baseline analysis
At baseline, 64 BM samples of the 67 patients were analysed by qualitative PCR. According to this analysis, 34 were MBR+ (53Á1%), 5 were mcr positive (mcr+; 7.8%), 4 showed a minor BCL2 rearrangement (6Á3%) and the remaining 21 were negative (32Á8%). With regard to PB, 64 samples were analysed at baseline: 33 were MBR+ (51Á6%), 6 were mcr+ (9Á4%), 4 were minor BCL2 positive (minor BCL2+; 6.3%), 20 were negative (31Á3%) and 1 was not evaluable (1Á6%). Overall, taking into account qualitative PCR performed at baseline on PB and/or BM, 48/67 patients (71Á6%) showed a BCL2/IGH+ marker in at least one compartment (36 MBR, 6 mcr and 6 minor rearrangements) and 19/67 patients (28Á4%) were defined as MBRÀ/mcrÀ/minor BCL2À.
Paraffin-embedded LN of 19/67 cases were analysed by qualitative PCR, 12 of which were evaluable: 10/12 cases showed the same molecular marker identified in the PB and/ or BM (the identity was confirmed by Sanger sequencing), whilst 2/12 showed a MBR rearrangement that was negative for this marker in the PB/BM. Thus, no disease-unrelated BCL2+ rearrangement was documented among the evaluable lymph nodes.
Among the 36 cases that were MBR+ in the BM and/or PB at baseline by nested PCR, RQ-PCR was applied to 26 BM and 26 PB samples, and ddPCR to 25 BM and 25 PB samples (Table SIA (Table SIA) . Thus, 25 BM samples were evaluated by both methods, showing a concordant result in 19/25 samples (76%) and a discordant one in 6/25 (24%).
RQ-PCR was positive in 22/26 PB samples (84Á6%)-11/22 (50%) had a high tumour infiltration, 3/22 (13Á6%) showed a low infiltration, 8/22 (36Á4%) were PNQ -and negative in 4/26 samples (15Á4%). ddPCR was positive in 23/25 PB samples -11/23 (47Á8%) had a high tumour infiltration, 3/23 (13%) showed a low infiltration, 9 (39Á1%) were PNQ -and negative in 2/25 (8%) (Table SIB) .
Overall, among the 25 PB evaluated by both RQ-PCR and ddPCR, a concordant result was observed in 23/25 samples (92%) and a discordant one in 2/25 (8%). The degree of concordance between RQ-PCR and ddPCR in the detection of MBR+ samples at baseline was higher in the PB than in the BM, but this difference was not significant (P = 0Á32).
In 30/36 MBR+ patients with available follow-up, it was possible to correlate the tumour burden at diagnosis, quantified by RQ-PCR and/or ddPCR, with the subsequent relapses (Pulsoni et al, 2016 Figure S1A and B show that the tumour burden at diagnosis significantly predicts progression-free survival (PSF) only when quantified by ddPCR (log rank test, P-value 0Á0268 for ddPCR; P-value 0Á1627 for RQ-PCR). Finally, RQ-PCR and ddPCR were performed on 15 and 18 out of the 19 marker negative patients, respectively; this analysis revealed a notable recovery of MBR+ cases: 8/18 (44Á4%) by ddPCR and 4/15 (26Á7%) by RQ-PCR (Table SIC  and D) .
MRD analysis of MBR+ cases post-RT and post-R treatment
Of the 36 baseline MBR+ patients, 33 BM samples were evaluated by nested PCR after RT: 14 (42Á4%) were MRDÀ, while 19/33 (57Á6%) were persistently MRD+. Similarly, 32 PB samples were qualitatively evaluated after RT: 13/32 (40Á6%) were MRDÀ, while 19/32 (59Á4%) were MRD+.
Of the 19 patients who were MRD+ after RT, 13 received R treatment and 11 were subsequently re-evaluated by nested PCR: both PB and BM were MRDÀ in 9 cases (81Á8%) and MRD+ in 2 (18Á2%).
RQ-PCR and ddPCR were applied to evaluate MRD after RT and after R: the details of the two time-points are provided in the Supplementary material (Tables SIIA-B and SIIIA-B). Pooling together these data, the two methods provided a concordant result in 78Á8% of the BM samples (26/ 33) and 89Á3% of the PB samples (25/28).
RQ-PCR versus ddPCR: overall results
A total of 138 samples, 72 BM and 66 PB, from different time points (77 baseline, 45 after RT and 16 after R treatment), were analysed by both RQ-PCR and ddPCR (Table I, Fig 1) . A first analysis (Table IA) were RQ-PCR-/ddPCR Q or RQ-PCRÀ/ddPCR PNQ. Among these 37 samples, 33 (89Á2%) could be defined as "minor discordances" being PNQ with one approach and negative with the other; while 4/37 (10Á8%) represented the "major discordances" as they were quantifiable with one method and negative with the other (2 cases RQ-PCR Q/ ddPCRÀ and 2 RQ-PCRÀ/ddPCR Q); all 4 were positive by nested PCR.
Among the 33 "minor discordant samples", 17 were RQ-PCR PNQ/ddPCRÀ and 16 RQ-PCRÀ/ddPCR PNQ. Focusing on the 17 samples that resulted RQ-PCR PNQ/ddPCRÀ, we wondered whether they could be false positive by RQ-PCR or ddPCR sensitivity failures. Thus, we evaluated again by ddPCR, by doubling the amount of DNA (i.e. by using 6 replicates per sample), 12 of these 17 discordant samples (10 having a positivity in 1/3 replicates and 2 PNQ because the non-reproducibility of the Cycle threshold values -Ct). Similarly, we also tested one of the two major discordant samples, which resulted RQ-PCR Q/ddPCRÀ (the other was not re-tested due to lack of material). Overall, of the 13 samples analysed, 1/13 were negative (RQ-PCR PNQ sample that was positive only in 1/3 replicates), 9/13 resulted PNQ (all RQ-PCR PNQ samples that were positive only in 1/3 replicates) and 3/13 resulted Q (the major discordant and the two RQ-PCR PNQ samples with a non-reproducibility of the Ct values -see Discussion).
Through this six-replicate analysis (Table IB) , the concordance rate increased to 81Á9% (113/138 samples), given that "minor discordances" reduced to 22 and the "major discordances" reduced to 3. Of the latter, 2 samples (RQ-PCRÀ/ Moreover, no quantitative discordances (discrepancy ≥1 log) were recorded in the samples that were quantifiable by both methods. With regard to RQ-PCR PNQ samples (32/138, 23Á2%), the ddPCR analysis enabled the identifyication of 7 Q samples (21Á9%) and 19 PNQ ones (59Á4%), while only 6 showed a negative result (18Á7%).
Among the 66/138 RQ-PCR negative samples (47Á8%), ddPCR was able to recover 18 positive samples (27Á3%, 16 PNQ and 2 Q) and to provide a concordant negative result in 48/66 samples (72Á7%).
Comparison of the data obtained from PB and BM analysis
Paired BM and PB samples were evaluated by qualitative PCR at baseline, after RT and after R-treatment in 66, 33 and 11 patients, respectively, reaching a total number of 110 qualitative evaluations on both PB and BM samples. Qualitative PCR showed 59/110 (53Á6%) double positive results (PB+/BM+) and 42/110 (38Á2%) negative ones (PBÀ/BMÀ), while the discordant cases were 9/110 (8Á2%, 5PB+/BMÀ and 4PBÀ/BM+); all the discordances were observed at baseline and, for each case, the positive signal was translated in a patient's specific BCL2/IGH sequence. Each case was defined as positive if a signal was found in at least one compartment. Thus, 68 cases could be considered positive and 64/68 were identified by the sole qualitative evaluation of PB (94Á1%). This would theoretically allow to patients to be spared a BM aspirate in 58Á2% (64/110) of evaluations.
With regard to RQ-PCR analysis, 63 paired PB and BM samples were analysed (36 at baseline, 19 after RT and 8 after R-treatment): 25/63 (39Á7%) were PB+/BM+, 25/63 (39Á7%) were PBÀ/BMÀ and a discordant result between the two compartments was found in 13/63 (20Á6%, 8/13 PB PNQ/ BMÀ and 5/13 PBÀ/BM PNQ). Overall, 38/63 cases were positive by RQ-PCR and 33/38 (86Á8%) could be identified by the sole study of PB.
Similarly, 62 PB and the corresponding BM samples were evaluated by ddPCR (34 at baseline, 20 after RT and 8 after R-treatment): 25/62 (40Á3%) resulted PB+/BM+, 22/62 (35Á5%) were PBÀ/BMÀ and 15/62 resulted as discordant (24Á2%, 6 PB PNQ/BM-, 3 PB Q/BM-, 6 PB-/BM PNQ). Overall, 40/62 cases were positive by ddPCR and 34/40 (85%) could be identified by the sole study of PB.
Taken together, these data suggest that PB is a suitable source for serial BCL2/IGH analyses in localized FL, regardless of the methodology utilized.
Discussion
The importance of identifying a stable and reliable molecular marker for patients affected by different lymphoid malignancies is well established, as well as the usefulness of sensitive techniques to detect residual malignant cells that are the source of relapse. The RQ-PCR TaqMan approach also represents the validated and standardized quantitative method for MRD detection in FL (van Dongen et al, 2003) . Despite remarkable sensitivity and specificity, RQ-PCR has however important limitations, represented by the need of a standard curve and the dynamic nature of the detection that carries intrinsic fluctuations not fully eliminable. In addition, a substantial proportion of samples are defined as PNQ having a tumour burden between the sensitivity and the quantitative range of the method (Drandi et al, 2015) . Conversely, ddPCR has several theoretical advantages compared to RQ-PCR, most notably the possibility of providing an absolute quantification of the target DNA molecules and of avoiding the reference standard curve; moreover, it seems capable of providing a great accuracy and precision for the detection and quantification of molecular targets (Hindson et al, 2013; Huggett & Whale, 2013; Kiselinova et al, 2014) .
Our study focused on the comparison of different molecular approaches for the detection of BLC2/IGH rearrangement in a homogeneous series of patients with stage I/II FL. The aim was to investigate the applicability of ddPCR for lymphoma cell detection at diagnosis and for MRD assessment, and to validate this new technique by comparison with RQ-PCR. Given that there are currently no established guidelines for MRD analysis and interpretation by ddPCR, we chose to apply the European RQ-PCR MRD criteria to this new method. Moreover, the comparison of paired PB and BM samples was performed to identify the elective tissue for MRD assessment in localized FL.
The presence of lymphoma cells carrying a MBR, mcr or a minor BCL2 rearrangement in the PB and/or BM was determined by qualitative PCR in the majority of patients (71Á6%), who were defined as stage I/II FL according to the conventional staging procedures, including a negative BM histology. This figure is somewhat higher than what expected (Leich et al, 2016) , but it should be underlined that 6 cases (9%) were identified by the analysis of minor and newly defined BCL2 rearrangements, whilst the proportion of MBR+ and mcr+ cases (63%) is comparable with the one (66%) reported in our original experience (Pulsoni et al, 2007) , confirming the limits of the standard staging procedures.
The PB and/or BM samples related to the 36 MBR+ patients were evaluated at baseline and at MRD evaluation after RT and R using the standardized method, RQ-PCR, and the emergent one, ddPCR, reaching a number of 138 samples evaluated by both methods. A first analysis, performed by testing samples in triplicate for both RQ-PCR and ddPCR, enabled the identification of similar proportions of positive, negative and PNQ samples, with an overall concordance of 73Á2%. This non-optimal level of concordance is due to the presence in this series of a high proportion of very low infiltrated samples, i.e. PNQ (32, 23Á2%) or negative (66, 47Á8%) by RQ-PCR. This is in line with the localized nature of early stage FL in which PB and BM represent only the sites of contamination by circulating lymphoma cells, undetectable by conventional staging procedures, already at diagnosis. As a consequence, the RQ-PCR/ddPCR general levels of concordance were apparently lower if compared to the data reported by Drandi et al (2015) in advanced stage FL, mantle cell lymphoma and multiple myeloma (concordance level of 85Á1%, 12% of PNQ samples) and by our group in ALL (88% of concordance, 17% of PNQ samples), where the PB and BM represent highly infiltrated sites of disease. The subsequent six-replicate ddPCR analysis (see below) allowed the concordance rate between the two quantitative approaches to be increased up to 81Á9% (113/138), a figure that is comparable to those mentioned above. Moreover, by considering the 40 samples with a RQ-PCR burden ≥10
À4 and ≥10 À5 , the level of concordance with ddPCR was remarkably high (96Á9% and 97Á5%, respectively) and no quantitative discordances ≥1 log were recorded. In order to specifically investigate the nature of the PNQ samples, we investigated whether the RQ-PCR PNQ/ddPCRÀ samples (17/138) represented false positive cases by RQ-PCR or ddPCR sensitivity failures. We took into consideration that this seemingly higher sensitivity of RQ-PCR could be related to the different DNA input. In fact, in our original quantitative analysis, the starting amount of DNA was 500 ng per well in both RQ-PCR and ddPCR, but in ddPCR only 40 ll of the 20(MIX)+70(OIL) ll sample is aspirated, implying that only about 250 ng of DNA are finally used. On these bases, we re-tested 13 samples (12 RQ-PCR PNQ/ ddPCRÀ plus 1 RQ-PCR Q/ddPCRÀ) by ddPCR in six replicates, equalizing the DNA input between the methods. The results showed that 9 of the 12 RQ-PCR PNQ/ddPCRÀ samples became ddPCR PNQ (defined PNQ by RQ-PCR for having only one amplification in their replicates), 1/12 remained ddPCR negative, 2/12 (defined PNQ by RQ-PCR because of a non-reproducibility of the Ct replicates) plus the RQ-PCR Q/ddPCRÀ sample became ddPCR Q. Thus, the six-replicate analysis allowed the general concordance rate between the methods to be increased to 81Á9% and to recover, in terms of both positivity and quantification, one sample previously considered a "major discordance" i.e. RQ-PCR Q/ddPCRÀ. Of the remaining 3 "major discordant" samples, the available clinical and molecular follow-up supported the better accuracy of ddPCR in 2 RQ-PCRÀ/ddPCR Q samples belonging to the same patient at diagnosis. Full clinical correlations in larger series of FL patients will clarify the significance of the few "minor discordances".
Finally, we correlated the tumour burden at diagnosis, quantified by both RQ-PCR and ddPCR, with the PFS: ddPCR appeared more accurate than RQ-PCR in quantifying the tumour burden at diagnosis, showing a significant relapse predictivity (P = 0Á0268) that was not observed by RQ-PCR (P = 0Á1627). In this way, the absolute quantification of PML/RARA at diagnosis performed by ddPCR has been recently proven to define the relapse risk in acute promyelocytic leukaemia (Albano et al, 2015) . Clearly, guidelines for analysis and interpretation of ddPCR-based MRD data must be "universally" defined to validate the applicability of this technology and to define its possible superiority compared to RQ-PCR in the MRD evaluation of haematological malignancies. In this context, our study provides a novel contribution relative to the application of ddPCR in localized FL with very low levels of circulating disease.
A high level of concordance was observed in the detection of BCL2/IGH rearrangements in the PB and BM compartments of any single patient by both qualitative and quantitative approaches. Indeed, the study of the PB alone was sufficient to identify 94Á1% and 85% of patients with circulating lymphoma cells by qualitative and quantitative approaches, respectively, with no differences between RQ-PCR and ddPCR. It should be kept in mind that BCL2/IGH+ non-malignant B cells can be found in the PB of healthy individuals (Roulland et al, 2006) ; thus, the baseline identification of a clone in the PB compartment is not sufficient to define it as a FL-related marker. In our study, no disease unrelated BCL2+ rearrangements were documented, although this relates to only in a minority of cases, due to the retrospective retrieval of paraffin-embedded LNs for qualitative PCR and sequencing analysis, evaluable in 12 cases. Thus, in early stage FL we propose that PB and BM, as well as the biopsied LN, should be studied at diagnosis in order to prove the sequence identity of the rearrangement and to exclude non-lymphoma related circulating rearrangements (Hirt et al, 2008) ; then, to monitor the disease over time by studying the PB, limiting the BM only to cases with a negative PB, regardless of the applied methodology. This would allow more than half of the cases to avoid having a BM aspirate taken.
In order to understand the pathogenesis of early stage FL, we certainly recognize the value of better characterizing early stage FL without t(14;18) compared to those with t(14;18). Leich et al (2016) reported that, at variance from advanced FL, about 50% of early stage FL cases do not show a t(14;18) in the LN by fluorescence in situ hybridisation (FISH), but the over-expression of the BCL2 protein is still present in 69% of them. The molecular mechanisms underlying these cases certainly need to be elucidated. In the diagnostic setting, FISH could readily be employed as the front-line molecular test to detect t(14;18) in the LNs, as it can detect translocations arising at nearly all breakpoint sites in 64-100% of FL, with a superior diagnostic sensitivity to PCR. Alternatively, it has also been suggested that PCR, the less expensive and faster technique, could be used initially and that FISH could be used secondarily for PCRÀ cases (Gu et al, 2008) . However, the latter cases can clearly not be monitored for MRD.
Finally, a cost analysis based on a 96-well plate showed that the overall cost of ddPCR was two times higher than RQ-PCR (3Á04€ per well for ddPCR vs. 1Á5€ for RQ-PCR). However, ddPCR, which allows the development and use of a standard curve to be bypassed, increases the number of analysable samples, resulting in a substantial benefit in terms of cost reduction and labour intensiveness, sparing precious diagnostic tissues. On the other hand, although its turnaround time is longer than that of RQ-PCR (5Á5 vs. 3Á5 h), this is highly compensated by its easier and faster data interpretation.
In conclusion, in early stage FL, ddPCR is an accurate and promising method to quantify the disease at the time of diagnosis and to monitor MRD during the clinical follow-up, at least comparable to standard RQ-PCR. Moreover, it appears to be more accurate than RQ-PCR in quantifying the tumour burden at diagnosis, with greater relapse predictivity. Intra-patient analysis from paired BM and PB samples demonstrated a high concordance, suggesting that PB is a suitable source for serial BCL2/IGH MRD assessments in localized FL, regardless of the methodology utilized. Further studies with long-term clinical correlations are needed to optimize the ddPCR experimental and analytical conditions for MRD assessment in FL as well as in other haematological malignancies.
Authorship contributions
MC and LADN designed research, performed molecular analysis, analysed the data and wrote the paper; IDS performed molecular analysis, analysed the data and contributed to the writing of the paper; LC and VN performed molecular analysis and analysed the data; AP monitored the FL patients; IDG analysed the data, contributed to the writing and the revision of the paper; AG analysed the data and contributed to the revision of the paper; RF reviewed the design of the study, analysed and discussed the results and critically revised the paper. rank test P value 0Á0268). (B) PFS accordingto the tumour burden at diagnosis quantified by RQ-PCR. Quantifiable disease ≥10-5: n = 17, events 6 vs. PNQ/negative: n = 13, events: 3 (log-rank test P value 0Á1627). 
